6 Dimensions Capital

VFLO, a medical device startup, to build a cutting-edge medical device platform that would enable Chinese patients to access cutting-edge treatments. Established by a healthcare fund and a team of experienced industry professionals to create a leading medical device platform with a focus on making innovative therapies available to Chinese patients.

MitrAssist is a medical device company focused on addressing mitral valve regurgitation (MR) through an innovative and minimally invasive approach. The company has developed a proprietary mitral valve implant that complements the natural mitral valve rather than replacing or repairing it. This unique "valve-in-valve" technique enhances the functionality of the existing valve, providing an effective treatment option for patients suffering from MR. MitrAssist's implant is designed to address the challenges associated with MR, offering a solution that surpasses current minimally invasive alternatives. By prioritizing patient health and comfort, MitrAssist aims to significantly improve treatment outcomes for individuals with this condition.

Ignis Therapeutics is a life science company focused on developing innovative therapies for central nervous system (CNS) conditions. Committed to advancing treatment paradigms, the company aims to transform the approach to treating CNS disorders. Ignis Therapeutics is dedicated to creating products that significantly enhance the quality of life for patients while offering additional therapeutic options for healthcare providers. Through its emphasis on self-discovery and strategic development, Ignis Therapeutics seeks to address unmet medical needs in the CNS space.

Haoxinqing is an online medical service platform that specializes in mental psychology and chronic disease management. The company offers remote diagnosis and treatment services, allowing patients to access medical care conveniently from their homes. By focusing on these areas, Haoxinqing aims to enhance patient experience and improve health outcomes, making it easier for individuals to manage their mental health and chronic conditions effectively.

Exo Therapeutics, Inc. is a drug discovery and development company focused on addressing challenging pharmaceutical targets. Founded in 2018 and based in Cambridge, Massachusetts, the company utilizes its proprietary ExoSight platform to create a pipeline of drug candidates that target exosites, which are unique and distal binding pockets on enzymes. This innovative approach aims to reprogram enzyme activity, leading to precise and effective therapeutic outcomes, particularly in oncology and inflammation, while also minimizing potential side effects for patients. Exo Therapeutics is committed to unlocking breakthrough therapeutics through its team of experienced researchers and a deep understanding of complex disease mechanisms.

Lyvgen Biopharma Co. Ltd. is a biotechnology company based in Shanghai, China, focused on the research, development, and production of immuno-oncology drug candidates. Established in 2016, the company specializes in a cross-linking-dependent antibody platform that includes proprietary co-stimulation agonist biotherapeutics, such as the PD-1 antibody SSI-361. These products are designed to activate specific receptors within the tumor microenvironment while minimizing immune-mediated adverse effects on healthy tissues. In addition to its therapeutic offerings, Lyvgen Biopharma provides tumor immune agonistic antibodies and services in synthetic biology engineering, aimed at enhancing localized activation of the tumor microenvironment.

TScan Therapeutics, Inc. is a biopharmaceutical company dedicated to discovering and developing T cell receptor (TCR) engineered T cell therapies for cancer treatment. Its primary focus is on liquid tumors, with lead therapy candidates TSC-100 and TSC-101 aimed at addressing hematologic malignancies by targeting residual leukemia and preventing relapse following hematopoietic stem cell transplantation. In addition to its liquid tumor programs, TScan is advancing multiplexed TCR-T therapy candidates to tackle various solid tumors. The company employs a unique platform that identifies previously uncharacterized shared T cell antigens and assesses off-target TCR interactions, which supports the creation of TCR-T therapies with reduced off-target effects. Founded in 2018 and headquartered in Waltham, Massachusetts, TScan Therapeutics aims to transform cancer treatment through innovative T cell therapies.

Exo Therapeutics, Inc. is a drug discovery and development company focused on addressing challenging pharmaceutical targets. Founded in 2018 and based in Cambridge, Massachusetts, the company utilizes its proprietary ExoSight platform to create a pipeline of drug candidates that target exosites, which are unique and distal binding pockets on enzymes. This innovative approach aims to reprogram enzyme activity, leading to precise and effective therapeutic outcomes, particularly in oncology and inflammation, while also minimizing potential side effects for patients. Exo Therapeutics is committed to unlocking breakthrough therapeutics through its team of experienced researchers and a deep understanding of complex disease mechanisms.

MitrAssist is a medical device company focused on addressing mitral valve regurgitation (MR) through an innovative and minimally invasive approach. The company has developed a proprietary mitral valve implant that complements the natural mitral valve rather than replacing or repairing it. This unique "valve-in-valve" technique enhances the functionality of the existing valve, providing an effective treatment option for patients suffering from MR. MitrAssist's implant is designed to address the challenges associated with MR, offering a solution that surpasses current minimally invasive alternatives. By prioritizing patient health and comfort, MitrAssist aims to significantly improve treatment outcomes for individuals with this condition.

Kira Pharmaceuticals, established in 2017 and headquartered in Suzhou, China, is a biotechnology company focused on developing innovative therapies targeting the complement system to treat immune-mediated diseases.

Haoxinqing is an online medical service platform that specializes in mental psychology and chronic disease management. The company offers remote diagnosis and treatment services, allowing patients to access medical care conveniently from their homes. By focusing on these areas, Haoxinqing aims to enhance patient experience and improve health outcomes, making it easier for individuals to manage their mental health and chronic conditions effectively.

TScan Therapeutics, Inc. is a biopharmaceutical company dedicated to discovering and developing T cell receptor (TCR) engineered T cell therapies for cancer treatment. Its primary focus is on liquid tumors, with lead therapy candidates TSC-100 and TSC-101 aimed at addressing hematologic malignancies by targeting residual leukemia and preventing relapse following hematopoietic stem cell transplantation. In addition to its liquid tumor programs, TScan is advancing multiplexed TCR-T therapy candidates to tackle various solid tumors. The company employs a unique platform that identifies previously uncharacterized shared T cell antigens and assesses off-target TCR interactions, which supports the creation of TCR-T therapies with reduced off-target effects. Founded in 2018 and headquartered in Waltham, Massachusetts, TScan Therapeutics aims to transform cancer treatment through innovative T cell therapies.

Guoke Hengtai (Beijing) Medical Technology Co., Ltd. is a Chinese company established in February 2013 and headquartered in the Yizhuang Economic and Technological Development Zone of Beijing. It operates under the umbrella of Oriental Science and Technology Holding Group Co., Ltd., which is connected to the State-owned Assets Supervision and Administration Commission of the Chinese Academy of Sciences. GKHT Medical Technology specializes in the distribution and direct sales of medical devices, offering a range of professional services, including warehousing logistics, distribution channel management, and hospital SPD operation management. Since its inception, the company has demonstrated significant growth, achieving a compound annual growth rate of over 50%, and it is currently pursuing an initial public offering.

Ultivue develops multiplex biomarker assays for tissue phenotyping and digital pathology. Its products enable high-resolution fluorescent microscopy imaging, aiding life science research and potential clinical diagnostics.

NeuSpera Medical Inc. is a company based in San Jose, California, that specializes in the development and manufacturing of ultra-miniaturized implantable devices designed for neuromodulation therapy. Established in 2013, NeuSpera Medical utilizes its proprietary Mid-Field Powering technology, which harnesses the body as a natural waveguide to transmit energy, allowing for external powering of its implants. This innovative approach facilitates minimally invasive interventions aimed at treating chronic conditions such as Urinary Urgency Incontinence and chronic peripheral nerve pain. The company's focus on bioelectronic medicine positions it as a key player in advancing therapeutic solutions through its cutting-edge implantable technology.

HiberCell, Inc. is a clinical-stage biotechnology company founded in 2019 and based in New York. It focuses on developing innovative therapeutics aimed at preventing cancer relapse and metastasis, which are significant contributors to cancer-related mortality. The company’s therapeutic pipeline addresses mechanisms of treatment resistance and utilizes advanced technologies, including artificial intelligence and machine learning, to analyze multi-omic and phenotypic profiles of tumors. This approach aims to generate insights that link tumor characteristics to clinical outcomes, ultimately striving to improve patient survival and quality of life by enabling longer, cancer-free lives.

Halda Therapeutics is a research-stage drug discovery company dedicated to developing next-generation precision medicine. The company employs a unique therapeutic modality that serves as a platform for addressing various disease states. By focusing on the discovery of novel therapies that modify disease-causing pathways, Halda Therapeutics aims to enable healthcare providers to offer more targeted treatments for their patients. Through its innovative approach, the company seeks to advance the field of precision medicine and improve patient outcomes.

Founded in 2018 and headquartered in Boston, Massachusetts, Dewpoint Therapeutics is a biotechnology company dedicated to researching biomolecular condensates and cellular function. The company aims to develop innovative treatments for various diseases such as cancer, neurodegenerative disorders, immunology, cardiovascular conditions, women's health, and virology.

Kymera Therapeutics, Inc. is a biopharmaceutical company based in Watertown, Massachusetts, specializing in targeted protein degradation. Founded in 2015, the company employs a proprietary platform that utilizes the body's natural protein degradation system to selectively degrade disease-causing proteins. Kymera is advancing several therapeutic programs, including its IRAK4 program aimed at treating immunology-inflammation diseases such as hidradenitis suppurativa, atopic dermatitis, and rheumatoid arthritis. Additionally, it is developing the IRAKIMiD program for MYD88-mutated diffuse large B cell lymphoma and the STAT3 program targeting hematologic malignancies, solid tumors, and autoimmune diseases. By focusing on previously untreatable conditions and using innovative small molecule modalities, Kymera Therapeutics aims to revolutionize drug discovery and create effective treatments for challenging diseases.

Coherent Biopharma is a pharmaceutical company focused on developing innovative drug therapies for oncology and chronic diseases. The company specializes in bi-targeting drug development technology, utilizing its proprietary platforms, including the BEST™ Platform, C-PROTAC Platform, and Chronic Diseases Platform. These technologies enable the creation of drugs that target specific tissues or organ sites, enhancing the effectiveness of treatments for various chronic conditions. By advancing its bi-targeting drug conjugation technology, Coherent Biopharma aims to improve patient outcomes through more precise and effective therapeutic options.

Fulcrum Therapeutics, Inc. is a clinical-stage biopharmaceutical company based in Cambridge, Massachusetts, dedicated to developing novel therapies for patients with genetically defined diseases that have significant unmet medical needs. The company's lead product candidate, losmapimod, is a small molecule currently undergoing Phase 2b clinical trials for the treatment of facioscapulohumeral muscular dystrophy, a rare condition characterized by progressive muscle wasting and disability. Another key candidate, FTX-6058, aims to upregulate fetal hemoglobin to treat sickle cell disease and beta-thalassemia. Fulcrum is also actively researching drug targets for other genetic disorders, including Duchenne muscular dystrophy and Friedreich ataxia, as well as neurological and pulmonary diseases. The company has established collaborations with Acceleron Pharma to explore biological targets in pulmonary disease and with MyoKardia to develop therapies for genetic cardiomyopathies. Founded in 2015, Fulcrum Therapeutics continues to focus on improving patient outcomes in rare disease contexts.

WiseTek is a medical device company that develops minimally invasive surgical instruments. The company's products include disposable ureteroscopic catheters, cystoscopic catheters, disposable electronic bronchoscopes, and endoscope image processors. The company's goal is to provide minimally invasive surgical tools for the eyes that will make future surgical procedures and medical diagnoses safer, more accurate, and less invasive.

GloriousMed Technology is a Healthcare company.

Curon Biopharma is focused on developing drugs for immuno-oncology therapies. The company offers a range of innovative cancer immunotherapeutic agents aimed at overcoming the limitations of existing cancer treatment approaches. By providing advanced immunotherapies, Curon Biopharma enables physicians to enhance treatment options for their patients battling cancer.

Lyvgen Biopharma Co. Ltd. is a biotechnology company based in Shanghai, China, focused on the research, development, and production of immuno-oncology drug candidates. Established in 2016, the company specializes in a cross-linking-dependent antibody platform that includes proprietary co-stimulation agonist biotherapeutics, such as the PD-1 antibody SSI-361. These products are designed to activate specific receptors within the tumor microenvironment while minimizing immune-mediated adverse effects on healthy tissues. In addition to its therapeutic offerings, Lyvgen Biopharma provides tumor immune agonistic antibodies and services in synthetic biology engineering, aimed at enhancing localized activation of the tumor microenvironment.

iTeos Therapeutics is a biotechnology company focused on immuno-oncology, developing cancer therapies that target the tumor microenvironment to overcome immune suppression and enhance efficacy of existing treatments. The company pursues small molecule and antibody approaches, including EOS-850, a small molecule antagonist of the adenosine A2A receptor, and EOS-448, an antagonist of TIGIT, with early-stage clinical programs designed to restore immune activity against tumors. By modulating metabolic and immune pathways within the tumor microenvironment, iTeos aims to improve responses across cancer types and complement immune checkpoint therapies.

Brii Biosciences Limited is a biotechnology company focused on the research, development, and commercialization of innovative medicines for chronic and infectious diseases, including hepatitis B virus (HBV), human immunodeficiency virus (HIV), and multi-drug resistant infections. Founded in 2018, the company is headquartered in Durham, North Carolina, with additional offices in Shanghai, Beijing, and San Francisco. Brii Biosciences aims to enhance healthcare outcomes for patients in China by leveraging advanced technology and data. The company has established strategic partnerships with organizations such as AliHealth and Vir to further its mission. With a robust pipeline consisting of over 10 product candidates, Brii Biosciences is dedicated to addressing significant public health challenges both in China and globally, focusing on delivering better treatments and cures for life-threatening diseases.

GRAIL, Inc. is a healthcare company dedicated to advancing technologies for early cancer detection. Founded in 2015 and headquartered in Menlo Park, California, GRAIL has developed Galleri, a screening test aimed at asymptomatic individuals over 50 years old, and DAC, a diagnostic aid designed to expedite the resolution of cancer diagnoses in patients with clinical suspicions. The company also focuses on creating minimal residual disease tests and other post-diagnostic solutions. GRAIL's innovative approach includes a pan-cancer screening test that utilizes high-intensity sequencing to analyze circulating nucleic acids in blood, enabling the potential to detect various types of cancer at early stages.

FogPharma is a biotechnology company focused on developing innovative therapies for cancer treatment through its proprietary cell-penetrating mini proteins (CPMPs). Founded by Greg Verdine, a leader in drug discovery, the company aims to target cancer-causing proteins within cells that are typically inaccessible to traditional drugs. This novel approach allows for the neutralization of these proteins, potentially transforming the treatment landscape for cancer-related diseases. FogPharma collaborates with leading experts in cancer biology and therapy, fostering a network of researchers, investors, and cancer patients dedicated to advancing its mission. The company is committed to delivering this new class of medicines to improve patient outcomes and enhance quality of life for individuals affected by cancer.

Yiyao is also knwon as 111.com.cn. Yiyao is an online drug superstore where patients can buy over-the-counter medications, traditional Chinese remedies, and a variety of other health products including everything from sex toys to diet pills. 111.com.cn operates as an online portal for selling pharmaceutical products.

Forerunner Medical (Shanghai) Co., Ltd., established in 2009, specializes in the development and manufacturing of innovative medical devices aimed at minimally invasive treatments. The company focuses on creating low-temperature plasma radio-frequency generators and electrodes specifically designed for sports medicine and tumor treatment. By leveraging extensive domestic clinical data and advanced technology, Forerunner Medical aims to meet both domestic and global healthcare needs. The organization emphasizes the quality and safety of its products, ensuring high performance, aesthetic appeal, and user convenience. Its commitment to excellence is reflected in its state-of-the-art production equipment and professional expertise, which contribute to its competitive advantage in the medical device industry.

Shenzhen Kangtai Biological Products Co., Ltd. is a prominent company in the field of human vaccine research and development, specializing in the production and sales of various biological products. With research and development centers and industrial bases located in Shenzhen and Beijing, the company focuses on manufacturing key vaccines, including recombinant hepatitis B vaccine, Haemophilus influenzae type b conjugate vaccine, and measles-rubella combined live attenuated vaccine. Additionally, it produces a cell-free combination vaccine for Haemophilus influenzae type b and a 23-valent pneumococcal polysaccharide vaccine, among other products. As one of China's leading hepatitis B vaccine manufacturers, the company plays a significant role in public health by developing a broad range of vaccines to address various infectious diseases.

Viela Bio, Inc. is a clinical-stage biotechnology company based in Gaithersburg, Maryland, focused on the research and development of innovative treatments for severe inflammation and autoimmune diseases. The company's lead product candidate, inebilizumab, is a humanized monoclonal antibody targeting CD19, which is expressed on various immune system B cells. This candidate is being developed for multiple indications, including neuromyelitis optica spectrum disorder, kidney transplant desensitization, myasthenia gravis, and IgG4-related diseases. Additionally, Viela Bio is advancing VIB4920, aimed at preventing kidney transplant rejection and treating sjögren’s syndrome, as well as VIB7734, which targets cutaneous lupus erythematosus. The company has established a strategic collaboration with Mitsubishi Tanabe Pharma Corporation to develop and commercialize inebilizumab for autoimmune diseases across several Asian markets. Founded in 2017, Viela Bio aims to address critical pathways underlying these diseases and improve patient outcomes globally.

Engine Biosciences, established in 2014 and headquartered in Singapore, specializes in drug discovery and cellular reprogramming. The company's core offering is a validated platform that combines artificial intelligence and genetic perturbation to uncover gene interactions and biological networks. This platform enables researchers and drug developers to create targeted therapies and apply precision medicine. Engine Biosciences caters to prominent American corporations and research institutions, accelerating and reducing the costs of R&D for new medical therapies.

NeuSpera Medical Inc. is a company based in San Jose, California, that specializes in the development and manufacturing of ultra-miniaturized implantable devices designed for neuromodulation therapy. Established in 2013, NeuSpera Medical utilizes its proprietary Mid-Field Powering technology, which harnesses the body as a natural waveguide to transmit energy, allowing for external powering of its implants. This innovative approach facilitates minimally invasive interventions aimed at treating chronic conditions such as Urinary Urgency Incontinence and chronic peripheral nerve pain. The company's focus on bioelectronic medicine positions it as a key player in advancing therapeutic solutions through its cutting-edge implantable technology.

Ultivue develops multiplex biomarker assays for tissue phenotyping and digital pathology. Its products enable high-resolution fluorescent microscopy imaging, aiding life science research and potential clinical diagnostics.

Gracell Biotechnologies Inc. is a clinical-stage biopharmaceutical company focused on the discovery and development of innovative cell therapies for cancer treatment. Based in Shanghai, China, Gracell's lead product candidates include GC012F, a dual-targeting autologous CAR-T therapy for multiple myeloma, and GC019F, which targets adult B cell acute lymphoblastic leukemia. Both candidates are currently undergoing Phase I clinical trials. Additionally, the company is advancing GC007F for B cell non-Hodgkin's lymphoma and GC027 for adult T cell acute lymphoblastic leukemia, among others. Gracell also has a range of earlier-stage product candidates addressing various cancer types, such as ovarian cancer and breast cancer. Founded in 2017, the company aims to provide effective cellular therapeutics to improve outcomes for patients with hematological malignancies and solid tumors.

Medeor Therapeutics, Inc. is a biotechnology company focused on researching, developing, and commercializing innovative cellular immunotherapies aimed at enhancing outcomes for organ transplant recipients. Based in San Mateo, California, Medeor Therapeutics has developed a specialized immunotherapy product for kidney transplant recipients known as MDR-10X. The company's cellular immunotherapies target organ transplant immune tolerance and immuno-oncology, providing healthcare providers with advanced techniques to preserve or improve kidney function and mitigate the risk of graft rejection more effectively than traditional immunosuppression therapies. Incorporated in 2012, Medeor Therapeutics is dedicated to transforming transplant outcomes through personalized treatment strategies.

AnchorDx is a biotechnology company specializing in next-generation sequencing techniques, particularly through the use of molecular liquid biopsies. This innovative approach allows for non-invasive access to genetic information, enabling patients to gain insights into their physiological conditions and better prepare for potential health issues. With a core team boasting over 20 years of experience in cancer genomics, genetics, and bioinformatics, AnchorDx aims to lead in precision medicine by developing comprehensive clinical applications and research platforms. The company fosters collaborations with various stakeholders, including hospitals, research institutes, and third-party testing agencies, to create a complete industrial chain that facilitates the transformation of academic research into clinical products. Through its commitment to developing independent intellectual property and competitive clinical testing solutions, AnchorDx provides accurate and comprehensive services to patients, healthcare providers, and medical institutions.

Helian Health, established in 2014 and headquartered in Hangzhou, China, specializes in providing Wi-Fi services to hospitals and developing online healthcare applications that support both patients and medical professionals. The company has created several applications, such as Xiaohe Yizhu, which enables healthcare providers to store health records in the cloud and share medical insights, and Hejiankang, which offers personalized health recommendations for employees. By focusing on the Internet of Things in healthcare, Helian Health has signed agreements with over 1,700 hospitals across 245 cities, including numerous top-tier facilities, thereby establishing itself as a leading Wi-Fi service provider within the sector. Additionally, the company offers various health management solutions that interpret personal health data and create tailored wellness programs for organizations. Through partnerships and innovative technology, Helian Health aims to enhance patient care and operational efficiency in medical institutions.

"Suzhou Jiecheng Medical Technology Co., Ltd." is a high-tech medical technology company with completely independent intellectual property rights and its patented technology is in a leading position in the world. The company was established in September 2009. The R&D team consists of Cardiologist Zhang Ji and several domestic and foreign R&D experts. The company's leading project is the development and production of the innovative "J-Valve Precision Positioning Heart Valve Implant System" technology. "J-Valve Precise Positioning Heart Valve Implant System" is a minimally invasive surgical technique that eliminates the need to open a chest and eliminates extracorporeal blood circulation. It can significantly reduce patient's surgical trauma, shorten postoperative recovery time, reduce patient's pain, and reduce The requirements of the patient's physical condition, thereby expanding the range of application of the disease, improving the efficacy of treatment, reducing the cost of surgery, so that the majority of patients need to replace the heart valve can be treated. Other similar products can only be implanted into the heart through the use of imaging technology. The J-Valve system can completely rely on its own positioning device to assist doctors in performing valve replacement surgery, thereby reducing the risk of surgery, easier to operate and master, and simplifying the heart valve Replacement process. The above advantages will help reduce the overall cost of the country's health care system, promote the reform of the health care system, reduce medical costs, and save social medical resources. At the same time, drastic changes in the long-term dependence on